Meeting
2013 ASCO Annual Meeting
Elevated pretreatment serum biomarkers and correlation with progression-free (PFS) and overall survival (OS) in first-line trastuzumab-treated metastatic breast cancer.
Authors
Suhail M. Ali
Penn State Hershey Medical Center, Hershey, PA
Suhail M. Ali , Kim Leitzel , Uchechi Anyanwu , Hui Ying Hou , Matthew Stephen Evans , Vikas Shrivastava , Wolfgang Köstler , Eva-Maria Fuchs , Francisco J. Esteva , Walter P. Carney , Allan Lipton
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 31, 2013 (suppl; abstr 622)
DOI
10.1200/jco.2013.31.15_suppl.622
Abstract #
622
Poster Bd #
11E
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Effect of serum HER2, TIMP-1, and CAIX on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: NCIC CTG MA.31.
First Author: Diep Ho
Poster
2013 ASCO Annual Meeting
Estimated life years saved with trastuzumab in first-line HER2+ metastatic breast cancer from 1999 to 2013.
First Author: Mark Danese
Poster
2018 ASCO Annual Meeting
Serum PD-L1 and outcomes in CCTG MA.31 phase 3 trial of anti-HER2 therapy in first-line HER2+ metastatic breast cancer patients (trastuzumab arm only).
First Author: Kim Leitzel
Poster
2015 ASCO Annual Meeting
Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).
First Author: Ahmad Awada